RecruitingPhase 3NCT07232719

A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight

A Phase 3b Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial

Sponsor

Eli Lilly and Company

Enrollment

250 participants

Start Date

Nov 17, 2025

Study Type

INTERVENTIONAL

Conditions

Obesity Overweight

Summary

The purpose of this study is to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction. Participation in the study will last about 65 weeks and may include about 18 visits.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a drug called retatrutide (LY3437943) — a new weight loss injection that works on multiple hormone pathways — in people who are overweight or obese. Researchers want to find out how well it helps people lose weight safely. **You may be eligible if...** - Your BMI is 30 or higher (obesity), OR - Your BMI is 27 or higher AND you have at least one weight-related condition like high blood pressure, abnormal cholesterol, sleep apnea, or heart disease - You have tried to lose weight through dieting at least once without long-term success **You may NOT be eligible if...** - Your weight has changed by more than 5 kg (11 lbs) in the past 90 days - You have had or are planning weight loss surgery - You have type 1 or type 2 diabetes - You or a family member has had medullary thyroid cancer or a condition called MEN-2 - You have had a heart attack or stroke in the past 90 days Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGRetatrutide

Administered SC

DRUGPlacebo

Administered SC

Locations(31)

Artemis Institute for Clinical Research

Riverside, California, United States

JEM Research Institute

Atlantis, Florida, United States

Headlands Research Orlando

Orlando, Florida, United States

Care Access - Tamarac

Tamarac, Florida, United States

Care Access - Arlington Heights

Arlington Heights, Illinois, United States

L-MARC Research Center

Louisville, Kentucky, United States

IMA Clinical Research Monroe - Armand

Monroe, Louisiana, United States

Pharmasite Research, Inc.

Baltimore, Maryland, United States

Clinical Research Professionals

Chesterfield, Missouri, United States

Clinvest Headlands Llc

Springfield, Missouri, United States

IMA Clinical Research Warren

Warren Township, New Jersey, United States

IMA Clinical Research Manhattan

New York, New York, United States

Trial Management Associates - Wilmington - Floral Parkway

Wilmington, North Carolina, United States

Cedar Health Research

Dallas, Texas, United States

Headlands Research-El Paso

El Paso, Texas, United States

Cedar Health Research - Euless

Euless, Texas, United States

Cedar Health Research - Fort Worth

Fort Worth, Texas, United States

Care Access - Houston

Houston, Texas, United States

IMA Clinical Research San Antonio

San Antonio, Texas, United States

FutureMeds - Birmingham

Birmingham, United Kingdom

Layton Medical Centre

Blackpool, United Kingdom

Bradford on Avon Health Centre

Bradford-on-Avon, United Kingdom

FutureMeds - Liverpool

Bromborough, United Kingdom

Cheadle Community Hospital

Cheadle, United Kingdom

HMC Health Group - Meadows Centre for Health

Hounslow, United Kingdom

St Bartholomew's Medical Centre

Oxford, United Kingdom

Atlantic Medical

Penzance, United Kingdom

The Adam Practice

Poole, United Kingdom

Woodstock Bower Surgery

Rotherham, United Kingdom

Rame Group Practice

Torpoint, United Kingdom

Albany House Medical Centre

Wellingborough, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07232719

Related Trials

Investigating the Impact of Obesity on Pubertal Development in Girls

NCT025836461 location

Heart Health Study in Washington D.C. to Develop a Community-Based Behavioral Weight Loss Intervention

NCT019277831 location

Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System

NCT011434543 locations

Diabetes and Heart Disease Risk in Blacks

NCT000018531 location

Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

NCT0728487533 locations